Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5Endocrine 5

Conditions

Carcinoma, Non-Small-Cell Lung 129Melanoma 90Squamous Cell Carcinoma of Head and Neck 88Breast Neoplasms 70Triple Negative Breast Neoplasms 64Parkinson Disease 4, Autosomal Dominant Lewy Body 45Head and Neck Neoplasms 45Lung Neoplasms 38Ovarian Neoplasms 37Neoplasms 37Neoplasm Metastasis 37Colorectal Neoplasms 37Stomach Neoplasms 36Carcinoma, Renal Cell 34Carcinoma, Transitional Cell 31Pancreatic Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Hepatocellular 27Recurrence 21Hodgkin Disease 21Uterine Cervical Neoplasms 20Endometrial Neoplasms 20Prostatic Neoplasms 18Esophageal Neoplasms 18Sarcoma 17Glioblastoma 17Brain Neoplasms 16Fallopian Tube Neoplasms 15Esophageal Squamous Cell Carcinoma 15Carcinoma, Squamous Cell 14

Interventions

trametinib 6dabrafenib 6pembrolizumab 5lenvatinib 5Paclitaxel 5Sorafenib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3pazopanib 2atezolizumab 2aldesleukin 2Taxes 2Radiotherapy 2Nivolumab 2Everolimus 2Bevacizumab 2zimberelimab 1selpercatinib 1sargramostim 1sacituzumab govitecan 1fosbretabulin 1fludarabine 1efatutazone 1cobimetinib 1ceritinib 1cemiplimab 1cabozantinib 1abemaciclib 1Vemurafenib 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Carcinoma, Anaplastic × pembrolizumab × Clear all
NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
25 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Saint Petersburg State University, Russia

Phase 2 Recruiting
20 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02688608 2022-02-10

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Stanford University

Phase 2 Completed
6 enrolled 10 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03211117 2020-03-25

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Mayo Clinic

Phase 2 Completed
3 enrolled 7 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡